hypercholesterolemia

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

NewsemiaFebruary 17, 2020

by NewsemiaFebruary 17, 2020020

AbstractBackground Proprotein convertase subtilisin/kexin type 9 inhibitor therapy is a treatment option for patients with familial hypercholesterolemia (FH) who are unable to reach low-density lipoprotein...

Cardiology

Aggressive Treatment for Severe Forms of Familial Hypercholesterolemia

NewsemiaFebruary 17, 2020

by NewsemiaFebruary 17, 202009

Aggressive Treatment for Severe Forms of Familial Hypercholesterolemia Source link...

Pediatrics

Statin Use in Children With Familial Hypercholesterolemia

NewsemiaFebruary 13, 2020

by NewsemiaFebruary 13, 202007

Statin Use in Children With Familial Hypercholesterolemia Source link...

Pediatrics

Public Policy Recs Updated for Familial Hypercholesterolemia

NewsemiaJanuary 3, 2020

by NewsemiaJanuary 3, 2020021

Goals include enhancing awareness of familial hypercholesterolemia as a global public health issue Source link...

Cardiology

Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.

NewsemiaDecember 7, 2019

by NewsemiaDecember 7, 201900

Related Articles Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia. Atherosclerosis. 2019 Nov 29;292:143-151 Authors: Lamiquiz-Moneo I, Restrepo-CÃ³rdoba MA, Mateo-Gallego...

Cardiology

Reply: Familial Hypercholesterolemia Causes Sudden Death

NewsemiaDecember 4, 2019

by NewsemiaDecember 4, 201900

Reply: Familial Hypercholesterolemia Causes Sudden Death Source link...

Cardiology

Familial Hypercholesterolemia Causes Sudden Death

NewsemiaDecember 4, 2019

by NewsemiaDecember 4, 201900

Familial Hypercholesterolemia Causes Sudden Death Source link...

Neurology

Unmet LDL-C Goals Common in ASCVD: PINNACLE, NHANES

NewsemiaNovember 27, 2019

by NewsemiaNovember 27, 201900

Two studies of patients with ASCVD — NHANES and the PINNACLE registry — show ‘a large burden of non- and undertreatment’ and ‘room for improvement’...

Cardiology

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia

NewsemiaNovember 11, 2019

by NewsemiaNovember 11, 201901

AbstractBackground Evolocumab and other anti-PCSK9 antibodies reduced adverse cardiovascular outcomes in clinical trials of high-risk patients over <3 years median treatment duration. Objectives The OSLER-1 trial...

Cardiology

Prevalence of hypercholesterolemia in Nigeria: a systematic review and meta-analysis.

NewsemiaNovember 8, 2019

by NewsemiaNovember 8, 201904

Related Articles Prevalence of hypercholesterolemia in Nigeria: a systematic review and meta-analysis. Public Health. 2019 Nov 04;178:167-178 Authors: Adeloye D, Abaa DQ, Owolabi EO, Ale...

Gastroenterology

Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism

NewsemiaNovember 1, 2019

by NewsemiaNovember 1, 201900

Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism Source link...

Cardiology

Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years

NewsemiaOctober 27, 2019

by NewsemiaOctober 27, 201901

Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years Source link...

Pediatrics

Long-Term Benefit of Early Statin Therapy for Familial Hypercholesterolemia

NewsemiaOctober 17, 2019

by NewsemiaOctober 17, 201900

Improved low-density lipoprotein levels and reduced cardiovascular event risk were shown after 20 years of statin treatment in children with FH. Source link...

Cardiology

Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.

NewsemiaSeptember 7, 2019

by NewsemiaSeptember 7, 201901

Related Articles Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. Atherosclerosis. 2019 Aug...

Cardiology

Cholesterol lowering attenuates pressure overload-induced heart failure in mice with mild hypercholesterolemia.

NewsemiaSeptember 5, 2019

by NewsemiaSeptember 5, 201901

Related Articles Cholesterol lowering attenuates pressure overload-induced heart failure in mice with mild hypercholesterolemia. Aging (Albany NY). 2019 Sep 04;11: Authors: Muthuramu I, Mishra M,...

Cardiology

Polygenic Risk Scores in Familial Hypercholesterolemia

NewsemiaJuly 28, 2019

by NewsemiaJuly 28, 201900

Polygenic Risk Scores in Familial Hypercholesterolemia Source link...

Cardiology

Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia

NewsemiaJuly 27, 2019

by NewsemiaJuly 27, 201900

AbstractBackground A pathogenic variant in LDLR, APOB, or PCSK9 can be identified in 30% to 80% of patients with clinically-diagnosed familial hypercholesterolemia (FH). Alternatively, ~20%...

Neurology

'Double Whammy': Where do PCSK9 Inhibitors Fit for Diabetes/ACS?

NewsemiaJuly 13, 2019

by NewsemiaJuly 13, 201902

Patients with diabetes as well as ACS and uncontrolled high cholesterol have a "double whammy" that makes them candidates for PCSK9 inhibitors to prevent CV...

A bacterium may limit cardiovascular risks of 1 in 2 people, study shows

NewsemiaJuly 1, 2019

by NewsemiaJuly 1, 201901

In 2007, Patrice Cani (FNRS-WELBIO researcher) and his team at the Louvain Drug Research Institute of University of Louvain, in close collaboration with Willem de...

Cardiology

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project.

NewsemiaJune 25, 2019

by NewsemiaJune 25, 201903

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. Curr Atheroscler Rep. 2019 Jun 22;21(9):36 Authors:...